Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

被引：0

作者：

Scheinberg, Phillip ^{[1
]}

Cle, Diego Villa ^{[2
]}

Devalet, Berangere ^{[3
]}

Giai, Valentina ^{[4
]}

Lekue, Cristina Barrenetxea ^{[5
]}

Lin, Hsuan-Yu ^{[6
]}

Nagy, Zsolt ^{[7
]}

Nishimura, Jun-ichi ^{[8
]}

Panse, Jens ^{[9
,10
]}

Piekarska, Agnieszka ^{[11
]}

Schubert, Joerg ^{[12
]}

Sunami, Kazutaka ^{[13
]}

Yenerel, Mustafa ^{[14
]}

Appius, Anita ^{[15
]}

Gentile, Brittany ^{[16
]}

Iwase, Shino ^{[15
]}

Patel, Himika ^{[17
]}

Sreckovic, Sasha ^{[18
]}

Kulasekararaj, Austin G. ^{[19
,20
,21
,22
]}

机构：

[1] Hosp Beneficencia Portuguesa, Sao Paulo, Brazil

[2] Univ Sao Paulo, Ribeirao Preto Sch Med, Ribeirao Preto, Brazil

[3] Univ Catholique Louvain UCLouvain, CHU UCL Namur, Dept Hematol, Yvoir, Belgium

[4] AOU Citta Salute & Sci Torino, Hematol, Turin, Italy

[5] Hosp Univ Basurto, Bilbao, Spain

[6] Changhua Christian Hosp, Dept Internal Med, Div Hematol Oncol, Changhua, Taiwan

[7] Semmelweis Univ, Dept Internal Med & Hematol, Budapest, Hungary

[8] Osaka Univ, Grad Sch Med, Osaka, Japan

[9] Univ Hosp RWTH Aachen, Dept Oncol Hemostaseol & Stem Cell Transplantat, Aachen, Germany

[10] Univ Hosp RWTH Aachen, Dept Oncol Hemostaseol & Stem Cell Transplantat, Aachen, Germany

[11] Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland

[12] Elblandklinikum Riesa, Riesa, Germany

[13] NHO Okayama Med Ctr, Dept Hematol, Okayama, Japan

[14] Istanbul Univ, Istanbul, Turkiye

[15] F Hoffmann La Roche Ltd, Basel, Switzerland

[16] Genentech Inc, South San Francisco, CA USA

[17] Canaudit Inc, Simi Valley, CA 93063 USA

[18] Genentech Inc, South San Francisco, CA USA

[19] Kings Coll Hosp London, NIHR Wellcome Kings Clin Res Facil, NHS Fdn Trust, London, England

[20] Kings Coll London, London, England

[21] Kings Coll London, Natl Inst Hlth & Care Res, London, England

[22] Wellcome Kings Res Facil, London, England

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-200745

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1313 / 1315

页数：3

共 50 条

[1] Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
Roeth, Alexander
He, Guangsheng
Brodsky, Andres
Chai-Adisaksopha, Chatree
Comia, Narcisa Sonia
Gaya, Anna
Hoeglund, Martin
Kelly, Richard J.
Kori, Ahlam Naila
Lee, Je-Hwan
Obara, Naoshi
Risitano, Antonio M.
Appius, Anita
Beveridge, Leigh
Gentile, Brittany
Zhang, Zilu
Han, Bing
Sreckovic, Sasha
BLOOD, 2024, 144 : 2687 - 2689
[2] Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 Trial
Lundberg, Pontus
de la Iglesia, Silvia
Kelly, Richard J.
Kulasekararaj, Austin
Nishimura, Jun-Ichi
Risitano, Antonio M.
Roeth, Alexander
Buatois, Simon
Chebon, Sammy
Patel, Himika
Kiialainen, Anna
BLOOD, 2023, 142
[3] Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies
Roeth, Alexander
Fu, Rong
He, Guangsheng
Alzahrani, Hazza A.
Chou, Sheng-Chieh
Hicheri, Yosr
Kazmierczak, Maciej
Recova, Viviane Lacorte
Uchiyama, Michihiro
Vladareanu, Ana Maria
Beveridge, Leigh
Buatois, Simon
Buri, Muriel
Shi, Dayu
Balachandran, Nadiesh
Srekovic, Sasha
Scheinberg, Phillip
BLOOD, 2023, 142
[4] The phase III, randomized, multicenter commodore 2 trial: results from the study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients naive to complement inhibitors
Roeth, A.
He, G.
Brodsky, A.
Chai-Adisaksopha, C.
Dumagay, T.
Demichelis Gomez, R.
Hoglund, M.
Kelly, R. J.
Lee, J. -H
Nishimura, J. -, I
Obara, N.
Risitano, A.
Gaya, A.
Appius, A.
Gentile, B.
Negricea, R.
Zhang, Z.
Buatois, S.
Han, B.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 294 - 295
[5] The phase III randomized, multicenter commodore 1 trial: comparison of crovalimab vs eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH)
Roeth, A.
Scheinberg, P.
Villa Cle, D.
Edwards, J.
Giai, V.
Hus, M.
Kim, J. S.
Barrenetxea Lekue, C.
Nagy, Z.
Nur, E.
Panse, J.
Ueda, Y.
Yenerel, M. N.
Appius, A.
Balachandran, N.
Chebon, S.
Gentile, B.
Buatois, S.
Kulasekararaj, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 200 - 201
[6] Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials
Panse, Jens
Cermak, Jaroslav
Kyselova, Olena
Gotoh, Akihiko
Sahin, Fahri
Schrezenmeier, Hubert
Chang, Alice C.
Gentile, Brittany
Uguen, Marianne
Han, Bing
BLOOD, 2023, 142
[7] Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Roeth, Alexander
He, Guangsheng
Tong, Hongyan
Lin, Zenghua
Wang, Xiaoqin
Chai-Adisaksopha, Chatree
Lee, Je-Hwan
Brodsky, Andres
Hantaweepant, Chattree
Dumagay, Teresita E.
Demichelis-Gomez, Roberta
Rojnuckarin, Ponlapat
Sun, Jing
Hoeglund, Martin
Jang, Jun Ho
Gaya, Anna
Silva, Fernando
Obara, Naoshi
Kelly, Richard J.
Beveridge, Leigh
Buatois, Simon
Chebon, Sammy
Gentile, Brittany
Lundberg, Pontus
Sreckovic, Sasha
Nishimura, Jun-ichi
Risitano, Antonio
Han, Bing
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1768 - 1777
[8] Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
Scheinberg, Phillip
Cle, Diego Villa
Kim, Jin Seok
Nur, Erfan
Yenerel, Mustafa N.
Barcellini, Wilma
Bonito, Debora
Giai, Valentina
Hus, Marek
Lee, Yoojin
Lekue, Cristina Barrenetxea
Panse, Jens
Ueda, Yasutaka
Buatois, Simon
Gentile, Brittany
Kiialainen, Anna
Patel, Himika
Sreckovic, Sasha
Uguen, Marianne
Edwards, John
Nagy, Zsolt
Kulasekararaj, Austin G.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1757 - 1767
[9] Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies
Roeth, Alexander
Fu, Rong
He, Guangsheng
Alzahrani, Hazzaa
Chou, Sheng-Chieh
Hicheri, Yosr
Kazmierczak, Maciej
Recova, Viviane Lacorte
Uchiyama, Michihiro
Vladareanu, Ana-Maria
Beveridge, Leigh
Buatois, Simon
Buri, Muriel
Compagno, Nicolo
Shi, Dayu
Balachandran, Nadiesh
Sreckovic, Sasha
Scheinberg, Phillip
EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (02) : 373 - 382
[10] Safety and efficacy of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Shepherd phase III clinical study results
Risitano, A. M.
Hillmen, P.
Young, N. S.
Schrezenmeier, H.
Schubert, J.
Urbano-Ispizua, A.
Coyle, L.
de Castro, C.
Fu, C. L.
Maciejewski, J. P.
Di Bona, E.
Antonioli, E.
Gianfaldoni, G.
Milano, F.
Amendola, A.
Kroon, H. A.
Rother, R. P.
Zanella, A.
Rodeghiero, F.
Iori, A. P.
Luzzatto, L.
Rotoli, B.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 88 - 88

← 1 2 3 4 5 →